Mvasi 25 mg (Bevacizumab SOLUTION) 25 MG

MVASI 25 MG is a solution containing bevacizumab, used for various medical conditions. This intravenous medication is manufactured by Amgen Canada Inc. and is commonly associated with specific therapeutic applications.

Strength

25 MG

Manufacturer / TM Owner

AMGEN CANADA INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

MVASI 25 MG is primarily used in the management of certain types of cancer. It works by targeting and inhibiting the growth of new blood vessels, which can help to slow the progression of the disease. This medication is often prescribed as part of a comprehensive treatment plan, which may include other therapies.

Side Effects

Common effects of MVASI 25 MG may include fatigue, high blood pressure, and changes in taste. Some individuals may also experience more serious side effects, such as bleeding or wound healing problems. It is important to discuss any concerns with a healthcare provider.

Precautions & Warnings

MVASI 25 MG should be handled with care and administered under the supervision of a healthcare professional. It is important to inform your healthcare provider about any allergies or medical conditions before starting treatment. Regular monitoring may be required to manage potential side effects.

Avoid Interactions

MVASI 25 MG may interact with other medications, including those that affect blood clotting or wound healing. It is important to discuss all current medications with a healthcare provider to avoid potential interactions. Alcohol and certain supplements may also affect the efficacy of this medication.

Frequently Asked Questions

MVASI 25 MG is used in the management of certain types of cancer, often as part of a comprehensive treatment plan.

MVASI 25 MG is administered intravenously by a healthcare professional.

Common side effects may include fatigue, high blood pressure, and changes in taste.

MVASI 25 MG may interact with other medications, so it is important to discuss all current medications with a healthcare provider.

MVASI 25 MG should be administered under the supervision of a healthcare professional, and regular monitoring may be required.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.